SAN FRANCISCO, Nov. 9, 2017 /PRNewswire/ -- Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics,today announced that Ken Horne, chief executive officer, will present at the upcoming 2017 Biotech and Money Inv€$tival Showcase, organized in partnership with Jefferies LLC, and the Trout Group EU Company Showcase in
Biotech and Money Inv€$tival Showcase in partnership with Jefferies LLC
Date: Tuesday, Nov. 14, 2017Time: 1:15 p.m. GMTLocation: The Hilton Waldorf, London
The Trout Group EU Company Showcase
Date: Tuesday, Nov. 14, 2017Time: 4 p.m. GMTLocation: Davis Polk & Wardwell LLP, London
Piper Jaffray 29th Annual Healthcare Conference
Date: Wednesday, Nov. 29, 2017Time: 1:10 p.m. ESTLocation: Lotte New York Palace, New York
About Symic Bio
Symic Bio is a biopharmaceutical company developing novel matrix-targeting biotherapeutics, a new category of therapeutics focused on matrix biology. These biotherapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is targeting the prevention of peripheral vein graft failure, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.
View original content:http://www.prnewswire.com/news-releases/symic-bio-to-present-at-upcoming-conferences-in-london-and-new-york-300552719.html
SOURCE Symic Bio
Subscribe to our Free Newsletters!
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...
Health insurance has emerged one of the fastest growing segments in the non-life insurance industry ...
Strabismus or squint is a failure of the two eyes to maintain proper alignment when looking at an ...View All